Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 Randomized Clinical Trial in the Russian Federation.

Though SPRs achieved with 3AV were numerically higher than 1AV at all timepoints examined, these differences did not reach statistical significance likely due to the small study sample size.

also in 111,027 other papers